Importantly, when the survivors from the SC144@HABN + anti-PD-L1 combo group were re-challenged on day 60 with MC38 tumor cells in the contralateral flank, 100% of mice resisted tumor re-challenge (Fig. 4l, m). Here, CD274 is linked to neoplasm.